公开(公告)号：WO2007089690A3

公开(公告)日：2008-12-11

申请号：PCT/US2007002367

申请日：2007-01-30

Applicant: CAPRION PHARMACEUTICALS INC ,  CHELSKY DANIEL ,  KEARNEY PAUL E ,  PARAMITHIOTIS EUSTACHE ,  HAMAIDI LYES ,  KONDEJEWSKI LESLIE H ,  LANOIX JOEL ,  HUGO PATRICE

Inventor： CHELSKY DANIEL ,  KEARNEY PAUL E ,  PARAMITHIOTIS EUSTACHE ,  HAMAIDI LYES ,  KONDEJEWSKI LESLIE H ,  LANOIX JOEL ,  HUGO PATRICE

IPC: A61K38/48 ,  C07H21/04 ,  C12N5/06 ,  C12N9/64 ,  C12P21/02 ,  C12Q1/68

CPC classification number: C07K14/4748 ,  C07K14/705 ,  G01N33/57423

Abstract: Surprisingly, the present inventors have discovered that expression of TAT- 042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

Abstract translation: 令人惊讶的是，本发明人已经发现，人类患者中TAT-042蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-042与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了鉴定抑制TAT-042表达或活性的化合物的方法，包括：使候选化合物与TAT-042接触，并检测所述化合物与所述TAT-042之间是否存在结合，或 检测TAT-042表达或活性的变化。 还包括用于鉴定调节TAT-042表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-042表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：WO2007084715A2

公开(公告)日：2007-07-26

申请号：PCT/US2007/001526

申请日：2007-01-19

Applicant: CAPRION PHARMACEUTICALS, INC. ,  PARAMITHIOTIS, Eustache ,  HAMAIDI, Lyes ,  CHELSKY, Daniel ,  HUGO, Patrice ,  KONDEJEWSKI, Leslie, H. ,  LANOIX, Joel ,  KEARNEY, Paul, E.

Inventor： PARAMITHIOTIS, Eustache ,  HAMAIDI, Lyes ,  CHELSKY, Daniel ,  HUGO, Patrice ,  KONDEJEWSKI, Leslie, H. ,  LANOIX, Joel ,  KEARNEY, Paul, E.

IPC: A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K48/00 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00

CPC classification number: G01N33/57423 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/3023 ,  C07K2317/34 ,  C07K2317/73 ,  G01N2500/00

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-031 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-031 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-031 expression or activity, comprising: contacting a candidate compound with a TAT-031 and detecting the presence or absence of binding between said compound and said TAT-031, or detecting a change in TAT-031 expression or activity. Methods are also included for the identification of compounds that modulate TAT-031 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-031 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

Abstract translation: 令人惊奇的是，本发明人已经发现人类患者中TAT-031蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-031与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-031表达或活性的化合物的方法，包括：使候选化合物与TAT-031接触，并检测所述化合物与所述TAT-031之间是否存在结合，或 检测TAT-031表达或活性的变化。 还包括用于鉴定调节TAT-031表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-031表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：WO2006133568A1

公开(公告)日：2006-12-21

申请号：PCT/CA2006/000993

申请日：2006-06-16

Applicant: CAPRION PHARMACEUTICALS INC. ,  KEARNEY, Paul Edward ,  LEKPOR, Kossi ,  SWAMY, Sajani ,  BUTLER, Heather ,  ENG, Kevin ,  HAYWARD, Clive ,  HUNTER, Joanna ,  OPITECK, Gregory ,  SCHIRM, Michael

Inventor： KEARNEY, Paul Edward ,  LEKPOR, Kossi ,  SWAMY, Sajani ,  BUTLER, Heather ,  ENG, Kevin ,  HAYWARD, Clive ,  HUNTER, Joanna ,  OPITECK, Gregory ,  SCHIRM, Michael

IPC: C12Q1/37 ,  C40B30/02 ,  C40B30/10 ,  G01N33/50 ,  G06F17/30

CPC classification number: G01N33/6848 ,  G01N30/7233 ,  G01N30/8686 ,  G01N30/8693 ,  G01N2030/8831

Abstract: Systems, methods, computer programming product, and databases for virtual mass spectrometry (VMS) enable the identification of polypeptides in samples without acquisition of MS/MS fragmentation spectra. Methods according to the invention employ databases containing records corresponding to polypeptides potentially present in samples. In addition to identifying polypeptides, such databases may be used for other purposes, including for example to correct experimental data, e.g., for analytical systemic errors.

Abstract translation: 用于虚拟质谱（VMS）的系统，方法，计算机程序产品和数据库使得能够在样本中鉴定多肽，而无需采集MS / MS碎片谱。 根据本发明的方法使用包含对应于可能存在于样品中的多肽的记录的数据库。 除了鉴定多肽之外，这样的数据库可以用于其他目的，包括例如校正实验数据，例如用于分析系统误差。

公开(公告)号：WO2006116681A2

公开(公告)日：2006-11-02

申请号：PCT/US2006016242

申请日：2006-04-28

Applicant: CAPRION PHARMACEUTICALS INC ,  HU MICHAEL ,  TSANG JOHN ,  JAITLY NAVDEEP ,  SWAMI SAJANI ,  HAMAIDI LYES ,  FILGUEIRA MARCELO ,  CHELSKY DANIEL ,  LANOIX JOEL ,  ENG KEVIN ,  THIBAULT PIERRE ,  FAUBERT DENIS ,  BRUNET SYLVAIN ,  OSTERMANN JOACHIM ,  BOULOS MARGUERITE ,  KEARNEY PAUL ,  BUTLER HEATHER

Inventor： HU MICHAEL ,  TSANG JOHN ,  JAITLY NAVDEEP ,  SWAMI SAJANI ,  HAMAIDI LYES ,  FILGUEIRA MARCELO ,  CHELSKY DANIEL ,  LANOIX JOEL ,  ENG KEVIN ,  THIBAULT PIERRE ,  FAUBERT DENIS ,  BRUNET SYLVAIN ,  OSTERMANN JOACHIM ,  BOULOS MARGUERITE ,  KEARNEY PAUL ,  BUTLER HEATHER

IPC: G01N33/574

CPC classification number: G01N33/57419

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-003 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-003 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-003 expression or activity, comprising: contacting a candidate compound with a TAT-003 and detecting the presence or absence of binding between said compound and said TAT-003, or detecting a change in TAT-003 expression or activity. Methods are also included for the identification of compounds that modulate TAT-003 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-003 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

Abstract translation: 令人惊奇的是，本发明人已经发现，人类患者中TAT-003蛋白的表达与癌症有关，而过度表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-003与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-003表达或活性的化合物的方法，包括：使候选化合物与TAT-003接触并检测所述化合物与所述TAT-003之间是否存在结合，或 检测TAT-003表达或活性的变化。 还包括用于鉴定调节TAT-003表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-003表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：WO2004061407A9

公开(公告)日：2004-10-07

申请号：PCT/CA2004000007

申请日：2004-01-05

Applicant: CAPRION PHARMACEUTICALS INC ,  SWAMY SAJANI ,  JAITLY NAVDEEP ,  FURTOS-MATEI ALEXANDRA ,  KEARNEY PAUL EDWARD ,  THIBAULT PIERRE

Inventor： SWAMY SAJANI ,  JAITLY NAVDEEP ,  FURTOS-MATEI ALEXANDRA ,  KEARNEY PAUL EDWARD ,  THIBAULT PIERRE

IPC: G01N24/00 ,  G01N33/68 ,  G06F19/00 ,  H01J49/00 ,  G01N

CPC classification number: G01N33/6848 ,  G01N33/6842 ,  Y10T436/24

Abstract: The invention described herein is a tool developed for the analysis of proteomic mass spectrometry (MS) data to identify and characterize glycoproteins. The tool is designed to perform four main tasks, separately, or as needed: optimize the selection of glycopeptides for MS/MS, identify glycopeptide spectra from MS/MS data, characterize the sugar moieties of identified glycopeptide spectra, and match the glycosylated precursor to its parent protein. The design and implementation for each of these components is described in more depth in this patent application.

Abstract translation: 本文描述的发明是开发用于分析蛋白质组质谱（MS）数据以识别和表征糖蛋白的工具。 该工具旨在分开或根据需要执行四个主要任务：优化MS / MS的糖肽选择，从MS / MS数据中鉴定糖肽谱，鉴定鉴定的糖肽谱的糖部分，并将糖基化前体与 其母体蛋白。 在本专利申请中更详细地描述了这些组件中的每一个的设计和实现。

公开(公告)号：WO2004049385A2

公开(公告)日：2004-06-10

申请号：PCT/IB2003/006376

申请日：2003-11-21

Applicant: CAPRION PHARMACEUTICALS, INC. ,  KEARNEY, Paul, Edward ,  JAITLY, Navdeep ,  ENG, Kevin

Inventor： KEARNEY, Paul, Edward ,  JAITLY, Navdeep ,  ENG, Kevin

IPC: H01J49/00

CPC classification number: H01J49/0027 ,  G01N27/44773 ,  G01N30/86 ,  G06F19/18

Abstract: The present invention features computer methods and systems for comparing biomolecules across biological samples. In these methods, mass spectrometry measurements are obtained on biomolecules in two or more samples. These measurements are then processed and analyzed by the methods described herein to render them more comparable. We refer to this technology as “Constellation Mapping” (CM). The resulting data, constellation maps, can be used to compare the abundance of biomolecules across samples, and, when done in real time, can be used to select differentially abundant biomolecules for subsequent LC/MS-MS.

Abstract translation: 本发明的特征在于用于比较生物样品上的生物分子的计算机方法和系统。 在这些方法中，在两个或多个样品中的生物分子上获得质谱测量。 然后通过本文所述的方法对这些测量进行处理和分析，以使它们更具可比性。 我们把这项技术称为“星座映射”（CM）。 所得到的数据，星座图可用于比较样品中生物分子的丰度，当实时完成时，可用于选择差异丰富的生物分子用于随后的LC / MS-MS。

公开(公告)号：WO2007005559A3

公开(公告)日：2009-04-16

申请号：PCT/US2006025483

申请日：2006-06-29

Applicant: CAPRION PHARMACEUTICALS INC ,  FILGUEIRA MARCELO ,  CHELSKY DANIEL ,  LANOIX JOEL ,  ENG KEVIN ,  THIBAULT PIERRE ,  FAUBERT DENIS ,  JAITLY NAVDEEP ,  BRUNET SYLVAIN ,  AGUILERA FRANK R M ,  TSANG JOHN S C ,  HU MICHAEL ,  OSTERMANN JOACHIM B ,  BOULOS MARGUERITE ,  KEARNEY PAUL E ,  BUTLER HEATHER ,  SWAMY SAJANI ,  HAMAIDI LYES

Inventor： FILGUEIRA MARCELO ,  CHELSKY DANIEL ,  LANOIX JOEL ,  ENG KEVIN ,  THIBAULT PIERRE ,  FAUBERT DENIS ,  JAITLY NAVDEEP ,  BRUNET SYLVAIN ,  AGUILERA FRANK R M ,  TSANG JOHN S C ,  HU MICHAEL ,  OSTERMANN JOACHIM B ,  BOULOS MARGUERITE ,  KEARNEY PAUL E ,  BUTLER HEATHER ,  SWAMY SAJANI ,  HAMAIDI LYES

IPC: C12Q1/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K49/00 ,  C07H21/04 ,  C07K14/00 ,  C12Q1/68 ,  G01N33/53

CPC classification number: G01N33/57419 ,  A01K2217/05 ,  A01K2217/075 ,  C07K14/4748 ,  G01N2500/04

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-005 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-005 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer com\ pounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-005 expression or activity, comprising: contacting a candidate compound with a TAT-005 and detecting the presence or absence of binding between said compound and said TAT-005, or detecting a change in TAT-005 expression or activity. Methods are also included for the identification of compounds that modulate TAT-005 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-005 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

Abstract translation: 令人惊奇的是，本发明人已经发现人类患者中TAT-005蛋白的表达与癌症有关，而过度表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-005与异常发育和生长相关，并且可用作鉴定抗癌药物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-005表达或活性的化合物的方法，包括：使候选化合物与TAT-005接触并检测所述化合物与所述TAT-005之间是否存在结合，或 检测TAT-005表达或活性的变化。 还包括用于鉴定调节TAT-005表达或活性的化合物的方法，包括：向细胞或细胞群体施用化合物，并检测TAT-005表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：WO2007087370A2

公开(公告)日：2007-08-02

申请号：PCT/US2007/001947

申请日：2007-01-25

Applicant: CAPRION PHARMACEUTICALS, INC. ,  CHELSKY, Daniel ,  KEARNEY, Paul, E. ,  PARAMITHIOTIS, Eustache ,  HAMAIDI, Lyes ,  KONDEJEWSKI, Leslie, H. ,  LANOIX, Joel ,  HUGO, Patrice

Inventor： CHELSKY, Daniel ,  KEARNEY, Paul, E. ,  PARAMITHIOTIS, Eustache ,  HAMAIDI, Lyes ,  KONDEJEWSKI, Leslie, H. ,  LANOIX, Joel ,  HUGO, Patrice

IPC: A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/395 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  A61K48/00

CPC classification number: G01N33/57423 ,  C07K14/4748 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2500/00

Abstract: Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

Abstract translation: 令人吃惊的是，本发明人已经发现，人类患者中TAT-038蛋白的表达与癌相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-038与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-038表达或活性的化合物的方法，包括：使候选化合物与TAT-038接触并检测所述化合物与所述TAT-038之间是否存在结合，或 检测TAT-038表达或活性的变化。 还包括用于鉴定调节TAT-038表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-038表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：WO2006133145A3

公开(公告)日：2006-12-14

申请号：PCT/US2006/021847

申请日：2006-06-06

Applicant: CAPRION PHARMACEUTICALS, INC. ,  LANOIX, Joel ,  ENG, Kevin ,  THIBAULT, Pierre ,  FAUBERT, Denis ,  JAITLY, Navdeep ,  BRUNET, Sylvain ,  AGUILERA, Frank, R.M. ,  TSANG, John, S.-C. ,  HU, Michael ,  OSTERMANN, Joachim, B. ,  BOULOS, Marguerite ,  KEARNEY, Paul, E. ,  BUTLER, Heather ,  SWAMY, Sajani ,  HAMAIDI, Lyes ,  FILGUEIRA, Marcelo ,  CHELSKY, Daniel

Inventor： LANOIX, Joel ,  ENG, Kevin ,  THIBAULT, Pierre ,  FAUBERT, Denis ,  JAITLY, Navdeep ,  BRUNET, Sylvain ,  AGUILERA, Frank, R.M. ,  TSANG, John, S.-C. ,  HU, Michael ,  OSTERMANN, Joachim, B. ,  BOULOS, Marguerite ,  KEARNEY, Paul, E. ,  BUTLER, Heather ,  SWAMY, Sajani ,  HAMAIDI, Lyes ,  FILGUEIRA, Marcelo ,  CHELSKY, Daniel

IPC: G01N33/53 ,  G01N33/577 ,  A61K38/00 ,  A61K48/00 ,  A61K39/395 ,  C07K5/00

Abstract: Surprisingly, the present inventors have discovered that expression of TAT- 007 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-007 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-007 expression or activity, comprising: contacting a candidate compound with a TAT-007 and detecting the presence or absence of binding between said compound and said TAT-007, or detecting a change in TAT-007 expression or activity. Methods are also included for the identification of compounds that modulate TAT-007 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-007 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

公开(公告)号：WO2004061407A2

公开(公告)日：2004-07-22

申请号：PCT/CA2004000007

申请日：2004-01-05

Applicant: CAPRION PHARMACEUTICALS INC ,  SWAMY SAJANI ,  JAITLY NAVDEEP ,  FURTOS-MATEI ALEXANDRA ,  KEARNEY PAUL EDWARD ,  THIBAULT PIERRE

Inventor： SWAMY SAJANI ,  JAITLY NAVDEEP ,  FURTOS-MATEI ALEXANDRA ,  KEARNEY PAUL EDWARD ,  THIBAULT PIERRE

IPC: G01N24/00 ,  G01N33/68 ,  G06F19/00 ,  H01J49/00 ,  G01N

CPC classification number: G01N33/6848 ,  G01N33/6842 ,  Y10T436/24

Abstract: The invention described herein is a tool developed for the analysis of proteomic mass spectrometry (MS) data to identify and characterize glycoproteins. The tool is designed to perform four main tasks, separately, or as needed: optimize the selection of glycopeptides for MS/MS, identify glycopeptide spectra from MS/MS data, characterize the sugar moieties of identified glycopeptide spectra, and match the glycosylated precursor to its parent protein. The design and implementation for each of these components is described in more depth in this patent application.

Abstract translation: 本文描述的本发明是开发用于分析蛋白质组质谱（MS）数据以鉴定和表征糖蛋白的工具。 该工具可分别或根据需要执行四项主要任务：优化MS / MS糖肽的选择，从MS / MS数据中鉴定糖肽谱，鉴定已鉴定糖肽谱的糖部分，并将糖基化前体与 其亲本蛋白质。 在这个专利申请中更详细地描述了每个这些组件的设计和实现。